Bioequivalence and Bioavailability Forum 08:58 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Shenanigans [BE/BA News]

posted by ElMaestro - Denmark, 2018-04-15 14:50  - Posting: # 18684
Views: 538

Hi all,

story from New York Times.

I have seen some cases of the same phenomenon in Europe, when wholesalers have been very forthcoming with supplies of trial material until they are told it is for use as a comparator in a BE trial. Then suddenly there is 'a problem with the supply chain' or some such vague excuse for quickly terminating the call.

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,768 posts in 3,999 threads, 1,255 registered users;
online 20 (0 registered, 20 guests [including 13 identified bots]).

It is not so much that I have confidence in scientists being right,
but that I have so much in nonscientists being wrong.    Isaac Asimov

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed